Dermatology billing demands precise lesion sizing, destruction vs. excision distinctions, Mohs stage coding, and pathology coordination—all critical to capturing the full value of every procedure. VeriMedix delivers specialty-trained dermatology RCM that minimizes undercoding and audit risk.
Dermatology is a procedure-intensive specialty where the accuracy of lesion measurement, anatomic site, and pathology documentation directly determines reimbursement. Benign lesion excision uses the 11400–11446 series, with code selection driven by (1) lesion size (diameter in centimeters, measured at excision including margins), (2) anatomic location (trunk/arms/legs vs. scalp/neck/hands/feet/genitalia vs. face/ears/eyelids/nose/lips/mucous membrane), and (3) whether the lesion is benign (11400 series) or malignant (11600–11646 series). A single coding error on size by 0.5 cm can result in thousands of dollars of underpayment or overpayment annually across a high-volume practice. Simple repair (12001–12021), intermediate repair (12031–12057), and complex repair (13100–13160) are bundled into the excision code when performed at the same anatomic site; however, repairs at a different anatomic site are separately billable with modifier -59. The size measured must be the excised specimen size, not the lesion size, and this must match the pathology report.
Destruction of benign and premalignant lesions adds a separate coding family. Cryotherapy, electrodesiccation, curettage, and laser destruction of actinic keratoses (AKs) use 17000 (first AK), 17003 (each additional 2–14 lesions), and 17004 (15 or more AKs in a single session). Destruction of benign lesions (other than warts or seborrheic keratoses) uses 17110 (up to 14 lesions) and 17111 (15 or more). Wart destruction uses 17110/17111 as well for flat warts; verruca vulgaris destruction is also covered by these codes. Shave excision (1102F series—11300 for trunk/arms/legs, 11301 for head/neck, etc.) is a different technique from excision and has its own code family based on lesion size in 0.5 cm increments. These distinctions require that providers document the technique used, the lesion size, and the lesion type clearly in the operative or procedure note.
Mohs micrographic surgery uses a distinct code set: 17311 for the first stage on the head/neck/hands/feet/genitalia/face (up to 5 tissue blocks) and 17312 for each additional stage at those sites; 17313/17314 for trunk/extremities first and additional stages. Each Mohs stage requires the surgeon to both excise the tissue and perform immediate histopathologic examination of the frozen sections. The Mohs surgeon bills for both the surgical and pathologic components in the same code—no separate pathology code is billed by the Mohs surgeon for their own sections. However, if a standard excision is converted to Mohs, only Mohs codes are billed. Post-Mohs reconstruction (14000–14350 for flaps, 15120–15121 for skin grafts, 12031–12057 for complex layered closures) is separately billable when performed. Biologics for moderate-to-severe psoriasis and atopic dermatitis (dupilumab J0222, secukinumab J3357, ixekizumab J2600, adalimumab J0135) represent a growing revenue line requiring prior authorization and J-code/NDC compliance.
Below are commonly billed codes our certified coders manage for dermatology practices. Always confirm payer-specific coverage and current code values.
| Code | Description | Billing note |
|---|---|---|
11402 | Excision, benign lesion including margins; trunk, arms, legs; excised diameter 1.1–2.0 cm | Size = excised specimen diameter including margins; document anatomic site; pairs with pathology (88305) |
11602 | Excision, malignant lesion including margins; trunk, arms, legs; excised diameter 1.1–2.0 cm | Malignant lesion excision; size drives code; 11600-11646 series; confirm malignancy with pathology report |
17000 | Destruction of premalignant lesions (actinic keratoses); first lesion | AK destruction (cryo, electro, laser); use 17003 for lesions 2–14 (per lesion add-on), 17004 for 15+ total |
17003 | Destruction of premalignant lesions; each additional lesion, 2–14 (list separately in addition to code for first lesion) | Add-on to 17000; bill one 17000 + units of 17003 for total 2–14 AKs; cannot bill 17003 without 17000 |
17311 | Mohs micrographic surgery, head/neck/hands/feet/genitalia/any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves/vessels; first stage, up to 5 tissue blocks | Mohs surgeon bills surgical AND pathologic interpretation in this single code; document stages, block count, tissue maps |
17312 | Mohs micrographic surgery (same anatomic sites as 17311); each additional stage, up to 5 tissue blocks | Add-on per additional stage; bill 17312 once per additional stage regardless of block count up to 5 |
11300 | Shave removal of epidermal or dermal lesion, trunk, arms, legs; lesion diameter 0.5 cm or less | Use 11300–11313 series based on site and size; shave technique ≠ excision technique; document clearly |
88305 | Level IV surgical pathology, gross and microscopic examination (skin biopsy, excision) | Billed by pathologist or practice lab; each excised specimen is one unit; ensure CPT-to-ICD alignment on path report |
J0222 | Injection, dupilumab (Dupixent), 1 mg | Biologic for atopic dermatitis, asthma; SC injection; prior auth; NDC required; JW/JZ for Medicare; 300 mg dose = 300 units |
Our standard operating procedures for dermatology revenue cycle management — the step-by-step workflow we follow on every claim:
These are the issues we see most often in dermatology billing — and exactly how we resolve them:
Billing a size tier larger than what is documented in the operative note (e.g., billing 11403 for a 2.1–3.0 cm specimen when the note says 1.8 cm) creates audit exposure and overpayment liability. Fix: Train physicians to record the exact excised specimen size in centimeters in the procedure note; implement a charge capture checklist that requires size confirmation before code selection; reconcile billed size against pathology gross specimen measurements quarterly.
CPT 17003 is an add-on code and cannot be billed without the parent code 17000. Some billing systems generate 17003 claims without the required 17000, causing claim rejection. Fix: Configure the billing system to require 17000 whenever 17003 units are entered; train coders on the AK destruction hierarchy.
Simple repair at the same anatomic site is included in the excision code and cannot be separately billed. However, complex repair (13100+) and repair at a different site are separately payable. Billing any repair alongside an excision without proper modifier -59 and same-site vs. different-site analysis results in denials. Fix: Create a decision tree for post-excision repair billing; only bill repair separately when it is complex OR at a different anatomic site; append modifier -59 or -XS with documentation.
Billing malignant excision codes (11600 series) before pathology confirmation is returned, or failing to update diagnosis codes when pathology returns benign, creates coding inaccuracy. Fix: Implement a pathology result reconciliation workflow where a coder reviews final pathology reports within 5 business days and updates ICD-10 codes to match confirmed diagnoses; hold claims for excisions with suspected malignancy until pathology results are received when feasible.
Some coders incorrectly assume that all reconstruction after Mohs is included in 17311/17312. In fact, reconstruction is separately billable and represents significant revenue. Fix: Train coders that 17311/17312 covers only the surgical excision and tissue processing/interpretation; document and bill all repair, flap, and grafting procedures separately with appropriate closure codes.
Verimedix works inside the systems dermatology practices already use, including:
Yes, with modifier -25 on the E/M to indicate it was a significant, separately identifiable service. The E/M should address a clinical issue distinct from the pre/post-service work of the excision. Document the clinical decision-making in the E/M note separately from the procedure note. Many payers accept this; some require the E/M to address a separate diagnosis from the excised lesion.
The size used for code selection is the excised specimen diameter including margins—not the clinical lesion size. Measure the specimen after excision; record this measurement in the operative note. This should correlate closely with the gross measurement on the pathology report. Discrepancies between the billed size and pathology gross measurement are a common audit flag.
Yes. CPT 17004 is used for destruction of 15 or more premalignant lesions (AKs) in a single session, regardless of technique. When 15 or more AKs are destroyed, bill 17004 as a standalone code—do not bill 17000 + 17003 in addition. When 1–14 AKs are destroyed, bill 17000 (first) + 17003 (each additional up to 13 add-on units).
Yes. Shave biopsies use 11102–11107 (effective since 2019); punch biopsies use 11104–11107; incisional biopsies use 11106–11107. These replaced the older 11100/11101 codes. Excisional biopsies (where the entire lesion is removed) may be coded as excision codes (11400 series) if the technique and documentation support it. Do not use punch or shave codes for full-thickness excisions with margins.
If the initial procedure was a shave/biopsy (11102–11107) and the pathology returns malignant, and a subsequent re-excision with wider margins is performed, bill the re-excision separately on the date it was performed using the malignant excision code (11600 series) based on re-excision specimen size. The initial biopsy and subsequent re-excision are separate encounters coded separately.
Payers typically require: body surface area (BSA) or PASI score documenting moderate-to-severe disease, documentation of inadequate response or contraindication to conventional topical therapies (topical steroids, calcineurin inhibitors) and/or systemic therapies (methotrexate, cyclosporine for psoriasis), current diagnosis confirmed by biopsy or clinical exam, and physician's letter of medical necessity. For psoriasis biologics, prior phototherapy failure may also be required.
Verimedix handles the entire dermatology revenue cycle — coding, submission, denials, and A/R — so your team can focus on patients.